If you have metastatic non-small-cell lung cancer ... Treatment that homes in on proteins that play a role in how your cancer grows in the body. Immunotherapy. Medicines that power your immune ...

Each year, 50,000 new lung cancer cases are diagnosed in France, with non–small cell lung cancer (NSCLC ... improves the ability to predict treatment responses. Another key advance concerns ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are ...

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises ...

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC).

PD-1 inhibitors, further establishing ivonescimab as a comprehensive treatment option for both first-line and later-line NSCLC ... integrated R&D innovation system with the comprehensive ...

for the treatment of non-small cell lung cancer (NSCLC). According to InvestingPro data, the company maintains a strong balance sheet, holding more cash than debt, which provides financial ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

"Novocure’s device for metastatic NSCLC treatment gains CE Mark" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...